BioTie Therapies Corp.'s Tozadenant (SYN115) Meets Primary and Multiple Secondary Endpoints in Phase 2b Study in Parkinson's Disease

Published: Dec 11, 2012

Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints. Full data from the study will be disclosed at upcoming medical conferences and in scientific publications.

Back to news